Who Owns Dianthus Therapeutics Stock?
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 122.94%
- Institutions (% of float)
- 123.09%
- Held by insiders
- 0.12%
- Institutional holders
- 376
- Institutions 99.9%
- Insiders 0.1%
- Public and other 0.0%
Who owns Dianthus Therapeutics stock?
Institutional investors own about 122.9% of Dianthus Therapeutics's shares, spread across 376 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.12% of DNTH.
The largest institutional holders are FMR, LLC (15.19%), T. Rowe Price Investment Management, Inc. (10.45%) and Blackrock Inc. (7.80%). Together, the top 10 institutions control 62.4% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their DNTH positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of DNTH
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 8.55M | 15.19% | +4.3% |
| T. Rowe Price Investment Management, Inc. | 5.89M | 10.45% | +51.4% |
| Blackrock Inc. | 4.39M | 7.80% | +6.5% |
| Wellington Management Group, LLP | 3.01M | 5.34% | -6.9% |
| Fairmount Funds Management LLC | 2.54M | 4.51% | 0.0% |
| State Street Corporation | 2.53M | 4.50% | +7.5% |
| Vanguard Capital Management LLC | 2.43M | 4.31% | +12.4% |
| Price (T.Rowe) Associates Inc | 2.21M | 3.92% | -12.2% |
| Avidity Partners Management, LP | 1.90M | 3.37% | -9.7% |
| Octagon Capital Advisors LP | 1.69M | 3.00% | -8.4% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of DNTH
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.65M | 2.93% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.59M | 2.83% |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.50M | 2.67% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.38M | 2.45% |
| iShares Trust-iShares Russell 2000 ETF | 1.22M | 2.17% |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.16M | 2.05% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 730.06K | 1.30% |
| T. Rowe Price New Horizons Fund, Inc. | 673.06K | 1.20% |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 624.59K | 1.11% |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 549.00K | 0.97% |
Frequently asked questions
Who is the largest shareholder of Dianthus Therapeutics?
FMR, LLC is the largest institutional shareholder of DNTH, owning 15.19% of shares outstanding (8.55M shares) as of its latest 13F filing.
What percentage of Dianthus Therapeutics is owned by institutions?
Institutions own about 122.9% of DNTH shares and 123.1% of the public float.
How much of Dianthus Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.12% of DNTH shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.